198 related articles for article (PubMed ID: 17525004)
21. Soluble LDL-immune complexes in type 2 diabetes and vascular disease.
Turk Z; Sesto M; Skodlar J; Ferencak G; Turk N; Stavljenić-Rukavina A
Horm Metab Res; 2002 Apr; 34(4):196-201. PubMed ID: 11987029
[TBL] [Abstract][Full Text] [Related]
22. Association between paraoxonase-1 activity and lipid peroxidation indicator levels in people living in the Antalya region with angiographically documented coronary artery disease.
Göçmen AY; Gümüşlü S; Semiz E
Clin Cardiol; 2004 Jul; 27(7):426-30. PubMed ID: 15298047
[TBL] [Abstract][Full Text] [Related]
23. [Role of small dense low-density lipoprotein in coronary artery disease patients with normal plasma cholesterol levels].
Koba S; Hirano T; Sakaue T; Sakai K; Kondo T; Yorozuya M; Suzuki H; Murakami M; Katagiri T
J Cardiol; 2000 Dec; 36(6):371-8. PubMed ID: 11190580
[TBL] [Abstract][Full Text] [Related]
24. Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease.
Kalogerakis G; Baker AM; Christov S; Rowley KG; Dwyer K; Winterbourn C; Best JD; Jenkins AJ
Clin Sci (Lond); 2005 Jun; 108(6):497-506. PubMed ID: 15634192
[TBL] [Abstract][Full Text] [Related]
25. Paraoxonase-1 (PON1) activity in patients with coronary artery diseases and in diabetic patients.
Amine K; Atouk A; Moussamih S; Saile R; Mikou A; Kettani A
Ann Biol Clin (Paris); 2011; 69(6):671-7. PubMed ID: 22123566
[TBL] [Abstract][Full Text] [Related]
26. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque.
Kowalski M
J Physiol Pharmacol; 2001 Aug; 52(1 Suppl 1):3-31. PubMed ID: 11795863
[TBL] [Abstract][Full Text] [Related]
27. Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans.
Lacinski M; Skorupski W; Cieslinski A; Sokolowska J; Trzeciak WH; Jakubowski H
Cell Mol Biol (Noisy-le-grand); 2004 Dec; 50(8):885-93. PubMed ID: 15704252
[TBL] [Abstract][Full Text] [Related]
28. HDL oxidability and its protective effect against LDL oxidation in Type 2 diabetic patients.
Sanguinetti SM; Brites FD; Fasulo V; Verona J; Elbert A; Wikinski RL; Schreier LE
Diabetes Nutr Metab; 2001 Feb; 14(1):27-36. PubMed ID: 11345163
[TBL] [Abstract][Full Text] [Related]
29. Interactions of serum hsCRP with apoB, apoB/AI ratio and some components of metabolic syndrome amplify the predictive values for coronary artery disease.
Rasouli M; Kiasari AM
Clin Biochem; 2006 Oct; 39(10):971-7. PubMed ID: 16963013
[TBL] [Abstract][Full Text] [Related]
30. Association of major modifiable risk factors among patients with coronary artery disease--a retrospective analysis.
Achari V; Thakur AK
J Assoc Physicians India; 2004 Feb; 52():103-8. PubMed ID: 15656042
[TBL] [Abstract][Full Text] [Related]
31. Lack of association between small dense low-density lipoprotein levels and coronary artery disease in chronic hemodialysis patients.
Yeo Y; Byun SW; Lee JY; Min WK; Park JS; Kim SB
Am J Nephrol; 2009; 30(3):310-4. PubMed ID: 19546529
[TBL] [Abstract][Full Text] [Related]
32. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
[TBL] [Abstract][Full Text] [Related]
33. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
[TBL] [Abstract][Full Text] [Related]
34. The relationship between paraoxonase1-192 polymorphism and activity with coronary artery disease.
Mohamed RH; Mohamed RH; Karam RA; Abd El-Aziz TA
Clin Biochem; 2010 Apr; 43(6):553-8. PubMed ID: 20026099
[TBL] [Abstract][Full Text] [Related]
35. [Paraoxonase 1 (PON1) activity and lipid parameters in Tunisian smokers].
Haj Mouhamed D; Ezzaher A; Araoud M; Neffati F; Douki W; Najjar MF
Ann Biol Clin (Paris); 2010; 68(2):143-7. PubMed ID: 20348046
[TBL] [Abstract][Full Text] [Related]
36. Plasma paraoxonase-1, oxidized low-density lipoprotein and lipid peroxidation levels in gout patients.
Jiang XL; Li M; Zhou JG; Yang QB; Du LJ; Du J
Cell Biochem Biophys; 2011 Nov; 61(2):461-6. PubMed ID: 21748243
[TBL] [Abstract][Full Text] [Related]
37. The role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study.
Gluba A; Pietrucha T; Banach M; Piotrowski G; Rysz J
Angiology; 2010 Feb; 61(2):157-65. PubMed ID: 19939821
[TBL] [Abstract][Full Text] [Related]
38. Can paraoxonase 1 polymorphisms (L55 M and Q192 R) protect children with type 1 diabetes against lipid abnormalities?
Fekih O; Triki S; Hellara I; Neffati F; Rejeb J; Ommezzine A; Chouchane S; Guediche MN; Bouslama A; Najjar MF
J Clin Lipidol; 2014; 8(3):249-55. PubMed ID: 24793345
[TBL] [Abstract][Full Text] [Related]
39. Serum paraoxonase phenotype distribution in exudative age-related macular degeneration and its relationship to homocysteine and oxidized low-density lipoprotein.
Javadzadeh A; Ghorbanihaghjo A; Bahreini E; Rashtchizadeh N; Argani H; Alizadeh S
Retina; 2012 Apr; 32(4):658-66. PubMed ID: 22030834
[TBL] [Abstract][Full Text] [Related]
40. Abnormalities in the relationship of paraoxonase 1 with HDL and apolipoprotein A1 and their possible connection to HDL dysfunctionality in type 2 diabetes.
Viktorinova A; Jurkovicova I; Fabryova L; Kinova S; Koren M; Stecova A; Svitekova K
Diabetes Res Clin Pract; 2018 Jun; 140():174-182. PubMed ID: 29626583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
